THERAPEUTICS
ADVANCED TREATMENT FOR BACTERIAL LUNG INFECTIONS
Due to the continuous emergence of drug-resistant strains of bacteria, in part driven by the rise of biofilm-caused chronic infections, current antibiotics are becoming less effective. Chronic, difficult-to-treat infections are contributing both to increased medical costs and accelerating the rise of antibiotic strains. In particular, general lung infections are the leading cause of infection mortality world-wide. These infections include hospital and community-acquired pneumonia, genetic disorder-related infection (cystic fibrosis), and pneumonia resulting from complications of other diseases (e.g. AIDS). The chronic and recurring infections due to Pseudomonas aeruginosa biofilms in the airway of cystic fibrosis (CF) patients are extremely difficult or impossible to eradicate, resulting in ongoing antibiotic therapy that typically results in the generation of antibiotic resistant strains. LifeUnit Inc. has developing small organic adjuvant molecules that enhance the ability of current antibiotics to eradicate bacterial biofilms.
KEY BENEFITS
THERAPEUTIC PIPELINE
Due to the continuous emergence of drug-resistant strains of bacteria, in part driven by the rise of biofilm-caused chronic infections, current antibiotics are becoming less effective. Chronic, difficult-to-treat infections are contributing both to increased medical costs and accelerating the rise of antibiotic strains. In particular, general lung infections are the leading cause of infection mortality world-wide. These infections include hospital and community-acquired pneumonia, genetic disorder-related infection (cystic fibrosis), and pneumonia resulting from complications of other diseases (e.g. AIDS). The chronic and recurring infections due to Pseudomonas aeruginosa biofilms in the airway of cystic fibrosis (CF) patients are extremely difficult or impossible to eradicate, resulting in ongoing antibiotic therapy that typically results in the generation of antibiotic resistant strains. LifeUnit Inc. has developing small organic adjuvant molecules that enhance the ability of current antibiotics to eradicate bacterial biofilms.
KEY BENEFITS
- Our lead compounds enable aminoglycoside and β-lactam antibiotics to better kill P. aeruginosa growing in biofilms and prevent the formation of new persisters in biofilms, while retaining “classical” activity versus planktonic bacteria.
- Our lead compounds show little apparent toxicity towards mammalian cells (using LDH Assays), thereby providing a robust therapeutic window.
- Our lead compounds display key drug-like properties (i.e., efficient synthesis, good solubility and stability in water, and strong receptor binding).
- Our lead compounds are amenable to nebulization for targeted drug delivery to infected lungs
- LifeUnit retains worldwide exclusivity to these lead compounds.
THERAPEUTIC PIPELINE
© 2020 LifeUnit, Inc